Advertisement

Psychopharmacology

, Volume 236, Issue 11, pp 3341–3352 | Cite as

Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans

  • Shanna BabalonisEmail author
  • Michelle R. Lofwall
  • Paul A. Sloan
  • Paul A. Nuzzo
  • Laura C. Fanucchi
  • Sharon L. Walsh
Original Investigation

Abstract

Rationale

Dozens of preclinical studies have reported cannabinoid agonist potentiation of the analgesic effects of μ-opioid agonists.

Objectives

The aim of this study was to determine if a cannabinoid agonist could potentiate opioid analgesia in humans using several laboratory pain models.

Methods

Healthy participants (n = 10) with/out current drug use/pain conditions completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Nine 8-h sessions were completed during which dronabinol (0, 2.5, 5 mg, p.o.) was administered 1 h before oxycodone (0, 5, 10 mg, p.o.) for a total of 9 test conditions. Outcomes included sensory threshold and tolerance from four experimental pain models (cold pressor, pressure algometer, hot thermode, cold hyperalgesia), along with participant- and observer-rated, performance and physiological effects.

Results

Oxycodone produced miosis (p < 0.05) and analgesic responses (e.g., pressure algometer [p < 0.05]), while dronabinol did not (p > 0.05). Depending on the dose combination, dronabinol attenuated or did not alter oxycodone analgesia; for example, dronabinol (2.5 mg) decreased the analgesic effects of oxycodone (10 mg) on pressure tolerance. Conversely, dronabinol increased oxycodone subjective effects (e.g., drug liking) (p < 0.05); oxycodone (5 mg) ratings of “high” were potentiated by 5 mg dronabinol (p < 0.05; placebo = 1.1 [± 0.7]; 5 mg oxycodone = 4.7 [± 2.2]; 5 mg dronabinol = 9.9 [± 8.4]; 5 mg oxycodone + 5 mg dronabinol = 37.4 [± 11.3]).

Conclusions

This study indicates that dronabinol did not enhance the analgesic effects of oxycodone and increased abuse- and impairment-related subjective effects. These data suggest that dronabinol may not be an effective or appropriate opioid adjuvant; it could potentially increase opioid dose requirements, while increasing psychoactive opioid effects.

Keywords

Cannabinoid Dronabinol Human Opioid Opioid sparing Pain 

Notes

Acknowledgments

Grants from the National Center for Research Resources and National Center for Advancing of Translational Sciences (KL2TR000116-04 [SB]; UL1TR001998 [UK CTSA]) and the University of Kentucky Center for Clinical and Translation Science provided support for this research. We thank Anne Estrup Olesen (Aalborg University Hospital, Denmark) for feedback on the experimental pain protocols; the staff at the University of Kentucky (UK) Center on Drug and Alcohol Research for research support: Amanda Kopca, Matthew Taylor, and Victoria Vessels; the UK Investigational Pharmacy for preparing study medication; and Dr. Samy-Claude Elayi for patient support.

Author Contributions

Shanna Babalonis, Michelle Lofwall, Paul Sloan, and Sharon Walsh were responsible for the study concept and design. Shanna Babalonis directly supervised the conduct of the study, interviewed and consented the participants, directed the statistical analyses, and wrote the manuscript. Michelle Lofwall and Laura Fanucchi conducted medical interviews and physical examinations and reviewed laboratory results. Michelle Lofwall, Paul Sloan, and Laura Fanucchi provided medical coverage and edited the manuscript. Paul Nuzzo trained the staff, provided technical support services, supervised daily operations, and conducted data analyses. Sharon Walsh, Michelle Lofwall, Paul Sloan, Laura Fanucchi, and Paul Nuzzo provided critical revisions of the manuscript for important intellectual content.

Funding

This study was funded by grants from the National Center for Research Resources and National Center for Advancing of Translational Sciences (KL2TR000116-04 [SB]; UL1TR001998 [UK CTSA]).

Compliance with ethical standards

The study was approved by the University of Kentucky Institutional Review Board and was conducted in accordance with the Helsinki guidelines for ethical research. A Certificate of Confidentiality was obtained from the U.S. Food and Drug Administration (FDA).

Conflict of interest

The authors declare that they have no conflict of interest.

Reference

  1. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL (2011) Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Thera 90(6):844–851Google Scholar
  2. Altis K, Schmidtko A, Angioni C, Kuczka K, Schmidt H, Geisslinger G, Lötsch J, Tegeder I (2009) Analgesic efficacy of tramadol, pregabalin and ibuprofen in menthol-evoked cold hyperalgesia. Pain 147(1–3):116–121PubMedGoogle Scholar
  3. Babalonis S, Hampson AJ, Lofwall MR, Nuzzo PA, Walsh SL (2015) Quinine as a potential tracer for medication adherence: a pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. J Clin Pharmacol 55(12):1332–1343PubMedPubMedCentralGoogle Scholar
  4. Babalonis S, Lofwall MR, Nuzzo PA, Walsh SL (2016) Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans. Addict Biol 21(1):146–158PubMedGoogle Scholar
  5. Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Int Med 174(10):1668–1673Google Scholar
  6. Beaulieu P (2006) Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 53(8):769–775PubMedGoogle Scholar
  7. Binder A, Stengel M, Klebe O, Wasner G, Baron R (2011) Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model. J Pain 12(7):764–773PubMedGoogle Scholar
  8. Bloomfield MA, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K, Costello H, Ogunbiyi MO, Bossong MG, Freeman TP (2018) The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharm Thera 195:132-161Google Scholar
  9. Boehnke KF, Litinas E, Clauw DJ (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17(6):739–744PubMedGoogle Scholar
  10. Bradford AC, Bradford WD (2017) Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff 36(5):945–951Google Scholar
  11. Califf RM, Woodcock J, Ostroff S (2016) A proactive response to prescription opioid abuse. NEJM. 374(15):1480–1485PubMedGoogle Scholar
  12. Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Chan G, Mattick RP, Blyth F (2018) Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health 3(7):e341–e350PubMedPubMedCentralGoogle Scholar
  13. Caputi TL, Humphreys K (2018) Medical marijuana users are more likely to use prescription drugs medically and nonmedically. J Addict Med 12(4):295–299PubMedGoogle Scholar
  14. Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74(11):1317–1324PubMedGoogle Scholar
  15. Cichewicz DL, McCarthy EA (2003) Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 304(3):1010–1015PubMedGoogle Scholar
  16. Cichewicz DL, Martin ZL, Smith FL, Welch SP (1999) Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 289(2):859–867PubMedGoogle Scholar
  17. Compton P, Kehoe P, Sinha K, Torrington MA, Ling W (2010) Gabapentin improves cold-pressor pain responses in methadone-maintained patients. Drug Alcohol Depend 109(1–3):213–219PubMedPubMedCentralGoogle Scholar
  18. Congressional Research Service (2018). The opioid epidemic and the Food and Drug Administration: legal authorities and recent agency action. Updated December 27, 2018. https://fas.org/sgp/crs/misc/R45218.pdf
  19. Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M (2018) Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 43:2046–2055PubMedPubMedCentralGoogle Scholar
  20. Dowell D, Haegerich TM, Chou R (2016) CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep 65(RR-1):1–49.  https://doi.org/10.15585/mmwr.rr6501e1 CrossRefPubMedGoogle Scholar
  21. Fattore L, Spano M, Melis V, Fadda P, Fratta W (2011) Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats. Br J Pharmacol 163(7):1550–1562PubMedPubMedCentralGoogle Scholar
  22. Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs. (B) a short-term “direct” addiction test. J Pharmacol Exp Ther 133:371–387PubMedGoogle Scholar
  23. Greco R, Demartini C, Zanaboni AM, Piomelli D, Tassorelli C (2018) Endocannabinoid system and migraine pain: an update. Front Neurosci 12:172PubMedPubMedCentralGoogle Scholar
  24. Greenwald MK, Stitzer ML (2000) Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 59(3):261–275PubMedGoogle Scholar
  25. Haghparast A, Shamsizadeh A, Samandari R, Omranifard A, Vaziri A, Razavi Y (2014) Cannabinoid receptors in the basolateral amygdala are involved in the potentiation of morphine rewarding properties in the acquisition, but not expression of conditioned place preference in rats. Brain Res 1565:28–36PubMedGoogle Scholar
  26. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL (2016) Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 41(8):1974–1982PubMedPubMedCentralGoogle Scholar
  27. Hill SY, Schwin R, Goodwin DW, Powell BJ (1974) Marihuana and pain. J Pharmacol Exp Thera 188(2):415–418Google Scholar
  28. Khan MIA, Walsh D, Brito-Dellan N (2011) Opioid and adjuvant analgesics: compared and contrasted. Am J Hosp Palliat Care 28(5):378–383PubMedGoogle Scholar
  29. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH (2010) Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. Pain 11(12):1420–1428Google Scholar
  30. Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG (2008) Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 109(1):101–110PubMedGoogle Scholar
  31. Li JX, Koek W, France CP (2012) Interactions between Delta(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys. Behav Pharmacol 23(8):754–761PubMedPubMedCentralGoogle Scholar
  32. Lile JA, Kelly TH, Charnigo RJ, Stinchcomb AL, Hays LR (2013) Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ9-THC in cannabis users. J Clin Pharmacol 53(7):680–690PubMedPubMedCentralGoogle Scholar
  33. Lucas P, Walsh Z, Crosby K (2016) Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug Alcohol Rev 35(3):326–333PubMedGoogle Scholar
  34. Maguire DR, France CP (2016) Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys. Behav Pharmacol 27(2–3 Spec Issue):249–257PubMedPubMedCentralGoogle Scholar
  35. Maguire DR, France CP (2018) Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Psychopharmacology 3:1–9Google Scholar
  36. Maguire DR, Yang W, France CP (2013) Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J Pharmacol Exp Ther 345(3):354–362PubMedPubMedCentralGoogle Scholar
  37. McLeod DR, Griffiths RR, Bigelow GE, Yingling JE (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum Comput 14:463–466Google Scholar
  38. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ (2007) Pharmacological management of chronic neuropathic pain—consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 12(1):13–21PubMedPubMedCentralGoogle Scholar
  39. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105(1–2):79–88PubMedGoogle Scholar
  40. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN (2008) Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 9(3):254–264PubMedGoogle Scholar
  41. Olesen AE, Andresen T, Staahl C, Drewes AM (2012) Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs. Pharmacol Rev 64(3):722–779PubMedGoogle Scholar
  42. Olfson M, Wall MM, Liu SM, Blanco C (2017) Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 175(1):47–53PubMedPubMedCentralGoogle Scholar
  43. Redmond WJ, Goffaux P, Potvin S, Marchand S (2008) Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin 24(4):1017–1024PubMedGoogle Scholar
  44. Roberts JD, Gennings C, Shih M (2006) Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530(1–2):54–58PubMedGoogle Scholar
  45. Schrepf A, Harper DE, Harte SE, Wang H, Ichesco E, Hampson JP, Zubieta JK, Clauw DJ, Harris RE (2016) Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain. 157(10):2217–2225PubMedPubMedCentralGoogle Scholar
  46. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR (2005) Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30(11):2046–2057PubMedGoogle Scholar
  47. Staahl C, Olesen AE, Andresen T, Arendt-Nielsen L, Drewes AM (2009) Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review. Br J Clin Pharmacol 68(2):149–168PubMedPubMedCentralGoogle Scholar
  48. United States Food and Drug Administration. Statement by FDA Commissioner Scott Gottlieb, M.D., on the agency’s ongoing work to forcefully address the opioid crisis. 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm618831.htm
  49. Varrassi G, Fusco M, Skaper SD, Battelli D, Zis P, Coaccioli S, Pace MC, Paladini A (2018) A pharmacological rationale to reduce the incidence of opioid induced tolerance and hyperalgesia: a review. Pain Ther 7(1):59–75PubMedPubMedCentralGoogle Scholar
  50. Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I (2007) Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 107(5):785–796PubMedGoogle Scholar
  51. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr (2008) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98:191–202PubMedPubMedCentralGoogle Scholar
  52. Walter C, Oertel BG, Lötsch J (2015) THC may reproducibly induce electrical hyperalgesia in healthy volunteers. Eur J Pain 19(4):516–518PubMedGoogle Scholar
  53. Welch SP (2009) Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 21(2):143–151PubMedGoogle Scholar
  54. Welch SP, Eads M (1999) Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 848(1–2):183–190PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Behavioral ScienceUniversity of Kentucky College of MedicineLexingtonUSA
  2. 2.Center on Drug and Alcohol ResearchUniversity of Kentucky College of MedicineLexingtonUSA
  3. 3.Department of PsychiatryUniversity of Kentucky College of MedicineLexingtonUSA
  4. 4.Department of AnesthesiologyUniversity of Kentucky College of MedicineLexingtonUSA
  5. 5.Department of Internal MedicineUniversity of Kentucky College of MedicineLexingtonUSA

Personalised recommendations